Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Johnson & Johnson's first quarter 2025 results present a multifaceted picture of a robust yet intricately challenged healthcare company.</li><li>The operational sales growth stood at 4.2%, even as they faced significant pressure due to the loss of exclusivity for STELARA, a multibillion-dollar pharmaceutical product.</li><li>Despite an 810 basis point headwind from STELARA, the Innovative Medicine sector showed resilience with an equal 4.2% growth, supported by strength in other key pharmaceuticals such as DARZALEX, which achieved a notable growth of over 20%.</li></ul>

Johnson & Johnson's first quarter 2025 results present a multifaceted picture of a robust yet intricately challenged healthcare company.The operational sales growth stood at 4.2%, even as they faced significant pressure due to the loss of exclusivity for STELARA, a multibillion-dollar pharmaceutical product.Despite an 810 basis point headwind from STELARA, the Innovative Medicine sector showed resilience with an equal 4.2% growth, supported by strength in other key pharmaceuticals such as DARZALEX, which achieved a notable growth of over 20%.

Johnson & Johnson Buys Halda: The Cancer Deal Wall Street Didn’t See Coming!

Founder, CEO, GSBR Research

Garvit Bhandari

Founder, CEO

Leading Provider of Equity and Investment Research

GSBR Research

We are an independent equity research provider focused on covering global markets. The aim of the research is to provide an unbiased view of the fundamentals of the company.

Event-Driven

<ul>
<li>Separation should unlock value by allowing J&amp;J to double-down on high-growth, higher-margin MedTech and pharma businesses.</li>
<li>SpinCo will emerge as one of the world’s largest pure-play orthopaedics firm with ~$9B revenue and global leadership across hips, knees, and trauma.</li>
<li>We see valuation upside. Transaction is likely to enhance JNJ’s sum-of-the-parts value.</li>
</ul>


Separation should unlock value by allowing J&amp;J to double-down on high-growth, higher-margin MedTech and pharma businesses.
SpinCo will emerge as one of the world’s largest pure-play orthopaedics firm with ~$9B revenue and global leadership across hips, knees, and trauma.
We see valuation upside. Transaction is likely to enhance JNJ’s sum-of-the-parts value.


Johnson & Johnson (NYSE: JNJ) To Spin Off Orthopaedics Business

Founder at Stock Spin-off Investing, Stock Spin-Off Investing

Richard Howe

Founder at Stock Spin-off Investing

Stock Spin-Off Investing

Generate attractive returns by taking advantage of inefficiencies in the stock spin-off market.

Stock Spin-offs

<ul><li>There is a good amount of froth in the market.</li><li>The “Fear &amp; Greed Index” has slipped into “Extreme Fear” which is usually a good contra-indicator.</li><li>For what it’s worth, I’m still finding plenty of ideas that look attractive from a “bottom up” perspective.</li></ul>

There is a good amount of froth in the market.The “Fear &amp; Greed Index” has slipped into “Extreme Fear” which is usually a good contra-indicator.For what it’s worth, I’m still finding plenty of ideas that look attractive from a “bottom up” perspective.

<ul><li>As Johnson & Johnson (JNJ) faces intensifying competition in the immunology landscape, recent reports indicate the healthcare behemoth is exploring the acquisition of Protagonist Therapeutics, a biotechnology firm currently collaborating with JNJ on the development of icotrokinra, a novel oral therapy targeting immune diseases like plaque psoriasis and ulcerative colitis.</li><li>The news has driven Protagonist’s stock up nearly 30%, valuing the company at around $4.2 billion.</li><li>JNJ already holds exclusive commercialization rights to icotrokinra, which analysts at Leerink Partners project could generate peak global sales of $9.5 billion.</li></ul>

As Johnson & Johnson (JNJ) faces intensifying competition in the immunology landscape, recent reports indicate the healthcare behemoth is exploring the acquisition of Protagonist Therapeutics, a biotechnology firm currently collaborating with JNJ on the development of icotrokinra, a novel oral therapy targeting immune diseases like plaque psoriasis and ulcerative colitis.The news has driven Protagonist’s stock up nearly 30%, valuing the company at around $4.2 billion.JNJ already holds exclusive commercialization rights to icotrokinra, which analysts at Leerink Partners project could generate peak global sales of $9.5 billion.

J&J’s Pursuit of Protagonist Therapeutics: A Strategic Move To Reinforce Immunology Leadership Post-Stelara!

Johnson & Johnson: An Insight Into Its Ortho Business Transformation

United States

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets.  The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Johnson & Johnson (JNJ US)

Johnson & Johnson Buys Halda: The Cancer Deal Wall Street Didn’t See Coming!

Johnson & Johnson's first quarter 2025 results present a multifaceted picture of a robust yet intricately challenged healthcare company. The...

Baptista Research

Johnson & Johnson (NYSE: JNJ) To Spin Off Orthopaedics Business

Spin-off of Orthopaedics business should unlock value by allowing JNJ to double-down on high-growth, higher-margin MedTech and pharma businesses

GSBR Research

Weekly Update (JNJ, LEN/MLR, SOLS)

There is a good amount of froth in the market. The “Fear & Greed Index” has slipped into “Extreme Fear” which is usually a good...

Richard Howe

J&J’s Pursuit of Protagonist Therapeutics: A Strategic Move To Reinforce Immunology Leadership Post-Stelara!

As Johnson & Johnson (JNJ) faces intensifying competition in the immunology landscape, recent reports indicate the healthcare behemoth is...

Baptista Research

Johnson & Johnson: An Insight Into Its Ortho Business Transformation

Johnson & Johnson's first quarter 2025 results present a multifaceted picture of a robust yet intricately challenged healthcare company. The...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)